SARTORIUS AG
ISIN: DE0007165607
WKN: 716560
02 July 2024 10:53AM

EQS-News: Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret

SARTORIUS AG · ISIN: DE0007165607 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1937941

Price (EoD) at the time of publication (02.07.2024): €173,60 | Last price update: €197,00 (30.08.2024)

EQS-News: SARTORIUS AG / Key word(s): Personnel
Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret (news with additional features)

02.07.2024 / 10:53 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

Göttingen, July 2, 2024

Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret

The long-standing CEO of Sartorius AG, Dr. Joachim Kreuzburg, has informed the company's Supervisory Board that after more than 20 years as CEO of the company, he will not be seeking another extension of his current contract when it expires in November 2025. The Supervisory Board has taken note of Kreuzburg's decision with great regret.

Kreuzburg has been at the helm of the company since 2003. After joining Sartorius AG in 1999, he was appointed to the Executive Board in 2002 at the age of 37 and became Chairman a few months later. During this time, Sartorius’ sales revenue increased more than 7-fold to around 3.4 billion euros and profits more than 26-fold to around 1 billion euros, the number of employees quadrupled to over 14,000 while the Group's stock market valuation increased from just over 90 million euros to more than 17 billion euros.

The Chairman of the Supervisory Board of Sartorius AG, Dr. Lothar Kappich, said: “Sartorius owes Joachim Kreuzburg an extraordinary amount. With his dynamic entrepreneurial qualities, he has transformed the company into an internationally leading and particularly profitable life science group, expanded the technology and product portfolio enormously and built up an outstanding team. We very much regret his decision. At the same time, we would like to thank him for informing us of his decision at an early stage and for continuing to be available to Sartorius until November 2025. The Supervisory Board will now initiate a succession process in an orderly and careful manner. I look forward to continuing to work so closely and well with Joachim Kreuzburg for another one and a half years until his departure.”

Kreuzburg said: “After so many years at the helm of this special company, I would like to have more space and time for new topics and projects in the future. For the upcoming phase of my life, I am ruling out taking on an executive top role, while I will continue to be involved in my mandates in business and science and will also engage in further business activities, especially in such innovation-driven sectors as biotechnology and medicine. After a phase of extraordinary growth, the entire life science industry is facing temporary challenges in the current "post-pandemic phase", while the prospects for the future remain excellent. The trough has been passed and I will continue to fully focus on Sartorius over the next year and a half and, together with my team, will work with all my energy to ensure that the company continues to develop more innovatively, faster and more profitably than the competition. At the same time, it was important to me to inform the Supervisory Board of my plans at an early point so that they can prepare for my succession without time pressure.”



A profile of Sartorius
Sartorius (XETRA: SRT3 | STR) is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2023, the company generated sales revenue of around 3.4 billion euros. Currently, around 14,600 employees are working for customers around the globe.

Visit our newsroom and follow Sartorius on LinkedIn.

Contact
Petra Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com

 

Additional features:

File: 240702_Media Release_SAG_Contract CEO_en (1)


02.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SARTORIUS AG
Otto-Brenner-Straße 20
37079 Göttingen
Germany
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: info@sartorius.com
Internet: www.sartorius.com
ISIN: DE0007165607, DE0007165631
WKN: 716560 , 716563
Indices: DAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1937941

 
End of News EQS News Service

1937941  02.07.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1937941&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2019 2020 2021 2022 2023 2024e 2025e
Sales1 1.826,97 2.335,66 3.449,22 4.174,70 3.395,70 3.400,00 0,00
EBITDA1,2 495,80 636,70 1.134,26 1.410,40 962,70 955,00 0,00
EBITDA-Margin3 27,14 27,26 32,89 33,78 28,35 28,09 0,00
EBIT1,4 335,66 456,11 903,16 1.070,00 503,90 530,00 0,00
EBIT-Margin5 18,37 19,53 26,18 25,63 14,84 15,59 0,00
Net Profit (Loss)1 218,74 299,56 426,98 655,40 290,00 205,00 0,00
Net-Margin6 11,97 12,83 12,38 15,70 8,54 6,03 0,00
Cashflow1,7 377,19 511,53 865,81 734,20 853,60 880,00 0,00
Earnings per share8 3,06 4,37 8,08 9,57 4,94 2,90 4,00
Dividend per share8 0,35 0,70 1,25 1,43 0,73 0,73 1,23
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: -

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Sartorius ST
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
716560 DE0007165607 AG 15.908,26 Mio € 10.07.1990 Halten 9F3FHV2Q+JW
* * *
PE 2026e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
35,74 38,65 0,92 43,55 5,42 16,61 4,68
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
1,43 0,73 0,73 0,39%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
27.03.2025 18.04.2024 19.07.2024 17.10.2024 16.02.2024
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+0,32%
189,40 €
ATH 834,00 €
+3,07% -4,31% +9,86% -24,84% +2.674,28%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2025          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2025 by Gereon Kruse #BGFL